Interleukin 1 Receptor Antagonist Protein (Anakinra)

Subscribe to Selected New Research on Interleukin 1 Receptor Antagonist Protein

1067 relevant articles (94 outcomes, 168 trials/studies) found for this Drug

Description: A ligand that binds to but fails to activate the INTERLEUKIN-1 RECEPTOR. It plays an inhibitory role in the regulation of INFLAMMATION and FEVER. Several isoforms of the protein exist due to multiple ALTERNATIVE SPLICING of its mRNA.

Also Known As:

Anakinra; Kineret; IL-1Ra; Amgen Brand of Anakinra; Antril; IL-1 Inhibitor, Urine; IL1 Febrile Inhibitor; Interleukin 1 Inhibitor, Urine; Synergen Brand of Anakinra; Urine-Derived IL1 Inhibitor; Anakinra Amgen Brand; Anakinra Synergen Brand; Febrile Inhibitor, IL1; IL 1 Inhibitor, Urine; IL1 Inhibitor, Urine-Derived; Urine Derived IL1 Inhibitor; Urine IL-1 Inhibitor

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Intercellular Signaling Peptides and Proteins: 9177

Cytokines: 34131

Interleukin 1 Receptor Antagonist Protein: 1067

human IL1RN protein

mouse Il1rn protein

Peptides: 16375

Intercellular Signaling Peptides and Proteins: 9177

Cytokines: 34131

Interleukin 1 Receptor Antagonist Protein: 1067

human IL1RN protein

mouse Il1rn protein

Biological Factors: 931

Intercellular Signaling Peptides and Proteins: 9177

Cytokines: 34131

Interleukin 1 Receptor Antagonist Protein: 1067

human IL1RN protein

mouse Il1rn protein

Experts

1.	Fleischmann, Roy: 4 articles (04/2007 - 04/2004)
2.	Liossis, Stamatis-Nick C: 3 articles (03/2008 - 04/2005)
3.	Emery, P: 3 articles (02/2008 - 09/2004)
4.	McDermott, Michael F: 3 articles (02/2008 - 02/2004)
5.	Tan, A L: 3 articles (02/2008 - 09/2004)
6.	McGonagle, D: 3 articles (02/2008 - 09/2004)
7.	Schiff, Michael H: 3 articles (01/2005 - 01/2004)
8.	Tesser, John: 3 articles (06/2004 - 04/2003)
9.	Schechtman, Joy: 3 articles (06/2004 - 04/2003)
10.	Bresnihan, B: 3 articles (05/2003 - 09/2002)

Related Diseases

1.	Rheumatoid Arthritis 01/01/2007 - "CONCLUSIONS: Our clinical experience confirms that anakinra is effective and safe in the treatment of rheumatoid arthritis. " 05/01/2004 - "This article reviews the preclinical, clinical, and postmarketing data on the safety and efficacy of anakinra in the treatment of rheumatoid arthritis and focuses on the pivotal clinical trials that led to FDA approval." 09/01/2002 - "A large, prospective safety study which allowed a wide-variety of comorbid conditions and concomitant medications demonstrated that anakinra therapy is a well-tolerated treatment for rheumatoid arthritis in the patient population seen by the practicing rheumatologist. " 07/01/2002 - "Anakinra shows promise for treating patients with rheumatoid arthritis." 01/01/2009 - "SELECTION CRITERIA: Randomized controlled trials comparing anakinra alone or in combination with DMARDs or biologics to placebo or other DMARDs or biologics in patients >18 years old with rheumatoid arthritis. " Order ALL the reference details at left...
2.	Syndrome 04/01/2006 - "CONCLUSION: Anakinra proved to be effective in three patients with Schnitzler's syndrome. " 12/01/2006 - "Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis." 05/01/2009 - "The efficacy of anakinra is dramatic in several hereditary auto-inflammatory syndromes. " 12/01/2007 - "Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra." 05/01/2005 - "Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome." Order ALL the reference details at left...
3.	Inflammation 07/01/2002 - "IL-1Ra and vIL-10 gene transfer using retroviral vectors ameliorates particle-associated inflammation in the murine air pouch model." 06/01/2008 - "The aim of our study was to characterize effects and mechanisms of IL-1ra administration on inflammation, apoptosis, and infiltration in renal I/R injury. " 09/01/2001 - "Our study demonstrates a decreased production of the anti-inflammatory compound IL-1ra, suggesting a propensity towards inflammation in patients with AD." 08/01/2000 - "IL-1ra has proved its therapeutic value in RA, but with the dose schedule in this study it does not behave as a specific radiopharmaceutical that is suitable for scintigraphic detection of inflammation." 03/01/1998 - "The results of these studies indicate that distal airway epithelial cell expression of human IL-1ra results in partial protection from IL-1alpha-induced airway inflammation and injury." Order ALL the reference details at left...
4.	Arthritis (Polyarthritis) 02/01/2000 - "CONCLUSION: This gene therapy, by combining highly efficient and stable rAAV gene delivery, disease-regulated gene expression, and the antiinflammatory effect of IL-1Ra, provides a valuable approach for long-term protection against, and prevention of, arthritis." 12/01/2005 - "However despite its rather disappointing effect in polyarticular arthritis, anakinra is being discovered as an effective treatment of systemic arthritis and children with mutations in the NALP3/CIAS1/PYPAF1 genes leading to autoimmune inflammatory disorders such as neonatal- onset multisystem inflammatory disease." 01/01/2003 - "CONCLUSION: Daily administration of recombinant IL-1Ra, injected at the same time as arthritis induction, is effective in blocking the occurrence of inflammatory as well as destructive changes in CIA. " 01/01/2001 - "Recombinant human IL-1Ra (rhu-IL-1Ra) has been evaluated in RA in several randomised clinical trials and was shown to significantly reduce both the clinical manifestations of arthritis and the rate of progressive joint damage. " 07/01/1996 - "The IL-1Ra Arthritis Study Group." Order ALL the reference details at left...
5.	Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis) 06/01/2009 - "Higher anakinra doses may be more efficacious in treating the systemic inflammatory response in systemic onset juvenile idiopathic arthritis patients. " 02/01/2009 - "Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study." 04/01/2008 - "Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)." 03/01/2008 - "BACKGROUND: Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD). " 03/01/2008 - "Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Interleukin-1 (Interleukin 1)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Interleukin-1 Receptors (Interleukin 1 Receptor)
4.	TNFR-Fc fusion protein (etanercept)
5.	Methotrexate (Mexate)
6.	infliximab (Remicade)
7.	Interleukin-6 (Interleukin 6)
8.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
9.	Interleukins
10.	adalimumab (Humira)

Related Therapies and Procedures

1.	Injections
2.	Aftercare (After-Treatment)
3.	Stents
4.	Kidney Transplantation
5.	Subcutaneous Injections

Best Treatments:
Research Summary Report
on Rheumatoid Arthritis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1565 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>